Mekkawy Aml I, Eleraky Nermin E, Soliman Ghareb M, Elnaggar Mohamed G, Elnaggar Marwa G
Department of Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt.
Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
Pharmaceutics. 2022 Aug 18;14(8):1727. doi: 10.3390/pharmaceutics14081727.
Breast cancer is the most widespread cancer in women with rising incidence, prevalence, and mortality in developed regions. Most breast cancers (80%) are estrogen receptor-positive, indicating that disease progression could be controlled by estrogen inhibition in the breast tissue. However, drug resistance limits the benefits of this approach. Combinatorial treatment could overcome the resistance and improve the outcome of breast cancer treatment. In the current study, we prepared letrozole-(LTZSPs) and quercetin-loaded spanlastics (QuSPs) using different edge activators-Tween 80, Brij 35, and Cremophor RH40-with different concentrations. The spanlastics were evaluated for their average particles size, surface charge, and percent encapsulation efficiency. The optimized formulations were further examined using transmission electron microscopy, Fourier transform infrared spectroscopy, in vitro drug release and ex vivo skin permeation studies. The prepared spherical LTZSPs and QuSPs had average particle sizes ranged between 129-310 nm and 240-560 nm, respectively, with negative surface charge and high LTZ and Qu encapsulation (94.3-97.2% and 97.9-99.6%, respectively). The in vitro release study of LTZ and Qu from the selected formulations showed a sustained drug release for 24 h with reasonable flux and permeation through the rat skin. Further, we evaluated the in vitro cytotoxicity, cell cycle analysis, and intracellular reactive oxygen species (ROS) of the combination therapy of letrozole and quercetin either in soluble form or loaded in spanlastics against MCF-7 breast cancer cells. The LTZSPs and QuSPs combination was superior to the individual treatments and the soluble free drugs in terms of in vitro cytotoxicity, cell cycle analysis, and ROS studies. These results confirm the potential of LTZSPs and QuSPs combination for transdermal delivery of drugs for enhanced breast cancer management.
乳腺癌是女性中最常见的癌症,在发达地区其发病率、患病率和死亡率都在上升。大多数乳腺癌(80%)是雌激素受体阳性,这表明疾病进展可以通过抑制乳腺组织中的雌激素来控制。然而,耐药性限制了这种方法的疗效。联合治疗可以克服耐药性并改善乳腺癌治疗的效果。在本研究中,我们使用不同的边缘活化剂——吐温80、Brij 35和聚氧乙烯蓖麻油RH40——以及不同浓度制备了来曲唑负载的Spanlastics(LTZSPs)和槲皮素负载的Spanlastics(QuSPs)。对Spanlastics的平均粒径、表面电荷和包封效率百分比进行了评估。使用透射电子显微镜、傅里叶变换红外光谱、体外药物释放和离体皮肤渗透研究对优化后的制剂进行了进一步研究。制备的球形LTZSPs和QuSPs的平均粒径分别在129 - 310 nm和240 - 560 nm之间,表面带负电荷,LTZ和Qu的包封率较高(分别为94.3 - 97.2%和97.9 - 99.6%)。所选制剂中LTZ和Qu的体外释放研究表明,药物持续释放24小时,通量合理且能透过大鼠皮肤。此外,我们评估了来曲唑和槲皮素以可溶形式或负载在Spanlastics中联合治疗对MCF - 7乳腺癌细胞的体外细胞毒性、细胞周期分析和细胞内活性氧(ROS)。在体外细胞毒性、细胞周期分析和ROS研究方面,LTZSPs和QuSPs联合治疗优于单独治疗和游离的可溶药物。这些结果证实了LTZSPs和QuSPs联合用于药物经皮递送以加强乳腺癌管理的潜力。